Roozbeh Mohajer, M.D.
Investigator
Dr. Roozbeh Mohajer is a board‑certified hematologist and medical oncologist with extensive clinical, research, and leadership experience across oncology, hematology, and palliative medicine. He currently practices at the Palo Alto Medical Foundation, where he has served since 2019, providing comprehensive cancer care grounded in evidence‑based medicine and compassionate patient support. Dr. Mohajer completed fellowship training in Hematology/Oncology at Cook County Health and in Hospice and Palliative Medicine at Rush University Medical Center, where he later served as Assistant Professor of Medicine. His research spans lung cancer therapeutics, prognostication tools, and palliative care, with publications and presentations at national and international meetings. Dr. Mohajer is an active member of major professional societies such as ASCO, ASH, and ESMO, and has been recognized with multiple clinical and research awards. He is fluent in English and Farsi and maintains diverse interests including music, calligraphy, and outdoor sports.
Clinical trials
- Clinical trial
Adjuvant Grade II or III Meningioma JZP3507-202
A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma
Status: Open to Enrollment
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
Status: Closed to Enrollment
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
Status: Open to Enrollment
- Clinical trial
Metastasis Brain NEO212-01
An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors
Status: Open to Enrollment
- Clinical trial
Recurrent or Progressive IDH1 Mutated Glioma NEO100-01
An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
Status: Open to Enrollment